ID   SKN
AC   CVCL_3167
DR   CLO; CLO_0050881
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03470820
DR   BioSample; SAMN03472277
DR   cancercelllines; CVCL_3167
DR   Cell_Model_Passport; SIDM00377
DR   Cosmic; 1330908
DR   Cosmic-CLP; 1240215
DR   DepMap; ACH-001655
DR   EGA; EGAS00001000978
DR   GDSC; 1240215
DR   GEO; GSM827211
DR   GEO; GSM1670447
DR   JCRB; IFO50314
DR   JCRB; JCRB0173
DR   JCRB; FDSC0031
DR   PharmacoDB; SKN_1419_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_3167
DR   RCB; RCB0513
DR   Wikidata; Q54954754
RX   CelloPub=CLPUB00481;
RX   PubMed=556976;
RX   PubMed=2429643;
RX   PubMed=2448191;
RX   PubMed=9436037;
RX   PubMed=9573483;
RX   PubMed=10457904;
RX   PubMed=20215515;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Doubling time: 36 hours (Note=At 29th passage) (PubMed=556976).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.3%; Native American=0%; East Asian, North=0%; East Asian, South=87.84%; South Asian=7.96%; European, North=0%; European, South=3.89% (PubMed=30894373).
CC   Discontinued: JCRB; FDSC0031; true.
ST   Source(s): Cosmic-CLP=1240215; DepMap=ACH-001655; JCRB=IFO50314; JCRB=JCRB0173; RCB=RCB0513
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 9
ST   D18S51: 13,15
ST   D21S11: 31.2
ST   D3S1358: 16
ST   D5S818: 12,13
ST   D7S820: 8,12
ST   D8S1179: 13,15
ST   FGA: 22
ST   Penta D: 9
ST   Penta E: 5
ST   TH01: 8
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C6340; Uterine corpus leiomyosarcoma
DI   ORDO; Orphanet_213625; Leiomyosarcoma of the corpus uteri
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
//
RX   CelloPub=CLPUB00481;
RA   Kuno H., Yoshida T.;
RT   "Detection of human papillomavirus types 16, 18, and 33 in cell lines
RT   derived from human genital organs by polymerase chain reaction.";
RL   Res. Commun. Inst. Ferment. 18:6-12(1997).
//
RX   PubMed=556976;
RA   Ishiwata I., Nozawa S., Nagai S., Kurihara S., Mikata A., Okumura H.;
RT   "Establishment of a human leiomyosarcoma cell line.";
RL   Cancer Res. 37:658-664(1977).
//
RX   PubMed=2429643; DOI=10.1111/j.1447-0756.1986.tb00192.x;
RA   Ishiwata I., Ishiwata C., Nozawa S., Ishikawa H.;
RT   "CA125 production by gynecologic tumors in vitro and its modulation
RT   induced by dibutyl cyclic adenosine monophosphate.";
RL   Asia Oceania J. Obstet. Gynaecol. 12:285-290(1986).
//
RX   PubMed=2448191; DOI=10.1016/0090-8258(88)90151-5;
RA   Ishiwata I., Ishiwata C., Soma M., Ono I., Nakaguchi T., Ishikawa H.;
RT   "Tumor angiogenic activity of gynecologic tumor cell lines on the
RT   chorioallantoic membrane.";
RL   Gynecol. Oncol. 29:87-93(1988).
//
RX   PubMed=9436037;
RA   Soma M., Ishiwata I., Ishiwata C., Nakaguchi T., Ono I., Kiguchi K.,
RA   Hashimoto H., Tachibana T., Ishikawa H., Nozawa S.;
RT   "Tissue reconstruction of gynecologic tumor cells in the rotation
RT   culture system.";
RL   Hum. Cell 10:175-181(1997).
//
RX   PubMed=9573483;
RA   Ishiwata I., Tokieda Y., Ishiwata C., Okane N., Iguchi M., Sato K.,
RA   Ishikawa H.;
RT   "Effects of feeder cells (human cancer cell lines) on the development
RT   of mouse embryos by co-culture.";
RL   Hum. Cell 10:237-246(1997).
//
RX   PubMed=10457904;
RA   Ishiwata I., Sudo T., Kiguchi K., Ishikawa H.;
RT   "Tumor angiogenesis factors produced by cancer cells.";
RL   Hum. Cell 12:37-46(1999).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//